Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford’s PepGen Launches Into DMD With Next-Gen Oligonucleotide Platform

Aims To Challenge Sarepta

Executive Summary

Arising from an Oxford and Cambridge university collaboration, the spin-out has selected Duchenne muscular dystrophy as the first target for its peptide platform.

You may also be interested in...



Sarepta’s Next-Gen DMD Drug SRP-5051 Shows Advantages, But Safety Concerns Too

The next-generation DMD drug showed dramatic improvement on exon dystrophin and exon skipping, but small numbers and adverse events give pause.

Sarepta's DMD Gene Therapy: Durable Responses After Two Years

Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.

Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results

Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel